Provention Bio (PRVB) Confirms FDA Advisory Committee Votes in Favor of Benefits of Teplizumab Outweighing Risks in Support of Approval to Delay Clinical Type 1 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. BLZE
8. NKE
9. MU
10. ACN

Go back to Provention Bio (PRVB) Confirms FDA Advisory Committee Votes in Favor of Benefits of Teplizumab Outweighing Risks in Support of Approval to Delay Clinical Type 1 Diabetes

FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D)

May 27, 2021 9:45 PM EDT

RED BANK, N.J., May 27, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 10 yes and 7 no on the question, "Does the information provided in the background documents and presentations by the Applicant and FDA show that the benefits of teplizumab outweigh the risks in support of approval to delay clinical type 1 diabetes mellitus?".

... More